STOCK TITAN

Alpine Immune Sciences Inc - ALPN STOCK NEWS

Welcome to our dedicated news page for Alpine Immune Sciences (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpine Immune Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpine Immune Sciences's position in the market.

Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) shares updated clinical data for povetacicept in IgA nephropathy, showing UPCR reductions of over 60% at 36 weeks, remission, resolution of hematuria, and stable renal function. Successful end of phase 2 meeting with FDA supports advancement to phase 3 study. Key biomarkers Gd-IgA1 and Gd-IgA1/C3 ratios significantly reduced. Monthly dosing well-tolerated with no severe infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.9%
Tags
-
Rhea-AI Summary
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion: A Strategic Move in Immunotherapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.9%
Tags
-
Rhea-AI Summary
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion in Cash, Focusing on Povetacicept for IgA Nephropathy Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.9%
Tags
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) to present updated clinical data for povetacicept in IgA nephropathy patients at the World Congress of Nephrology. Investor event scheduled on April 15th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences clinical trial
-
Rhea-AI Summary
Alpine Immune Sciences presents promising translational data for povetacicept (ALPN-303) at SLEuro 14th European Lupus Meeting. Povetacicept demonstrates superior disease activity reduction in a lupus mouse model compared to WT TACI-Ig or B cell depletion. It shows increased distribution to disease-related organs. A phase 2 study in SLE (DENALI) is planned for 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
none
-
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) to participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. Remy Durand, Chief Business Officer, to join fireside chat. Investor meetings scheduled. Webcasts and replays available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences
Rhea-AI Summary
Alpine Immune Sciences, Inc. reports positive clinical data on povetacicept in IgA nephropathy and systemic lupus erythematosus. The company plans pivotal phase 3 trials for IgAN and phase 2 trials for SLE. Financially, Alpine saw a significant increase in collaboration revenue and a strong cash position, enough to fund operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.63%
Tags
-
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) will release its fourth quarter and full year 2023 financial results on March 18, 2024. The company focuses on developing treatments for autoimmune and inflammatory diseases. A conference call and webcast will be held on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences earnings
-
Rhea-AI Summary
Alpine Immune Sciences (ALPN) to participate in two healthcare conferences to discuss IgA Nephropathy and biopharma developments. Live webcasts and investor meetings scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
conferences
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) will participate in two upcoming healthcare conferences, the Guggenheim 6th Annual Biotechnology Conference and the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The Company will host investor meetings and fireside chats during the events, with live webcasts and replays available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences
Alpine Immune Sciences Inc

Nasdaq:ALPN

ALPN Rankings

ALPN Stock Data

4.23B
44.92M
4.64%
91.41%
8.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About ALPN

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.